New York, May 27, 2026, 10:03 EDT
Talphera Inc. traded at about $0.80 early Wednesday, off 2.8% from its last close. Only 1,493 shares traded as the company’s market cap hovered near $41.5 million. The stock lagged behind a stronger biotech sector, with SPDR S&P Biotech ETF up 0.9% and iShares Nasdaq Biotechnology ETF adding 0.8%. An ETF is a basket of securities that trades like a single stock.
Talphera’s most recent update was still its May 13 Q1 results and a corporate update, according to the investor page. Investors were left focused on trial timing, cash position, and when new data might hit, with no fresh announcement from the company.
Talphera is putting most of its hopes on Niyad, the company’s main pipeline drug for continuous renal replacement therapy, or CRRT, which is used for intensive-care dialysis. The company said the NEPHRO CRRT study has now passed 50% enrollment and it continues to target study completion in 2026.
The study aims to sign up 70 adults at as many as 14 intensive-care units in U.S. hospitals. Researchers are comparing Niyad to placebo in patients on renal replacement therapy who either can’t use heparin or have higher bleeding risk. The main goal looks at clotting time in the filter circuit during the initial 24-hour window.
Talphera CEO Vince Angotti said in a May 13 update the company hit 50% enrollment in early March, and that figure has “well exceeded” since. When a micro-cap like Talphera moves along the trial calendar, the stock often moves too.
Niyad is set up as a regional anticoagulant. It’s supposed to stop clotting in the extracorporeal dialysis circuit without thinning the patient’s blood overall. Talphera says the FDA gave it breakthrough device status and it would count as a device, since nafamostat is aimed to work in the circuit.
Talphera CFO Raffi Asadorian told investors on the May 13 call they plan to announce last patient out, with top-line data expected “within a month.” He said current cash plus expected conditional financing should give the company enough capital through at least a potential Niyad PMA nod next year. PMA is a premarket approval process at the FDA for some devices. Chief Medical Officer Dr. Shakil Aslam said nafamostat is “not dependent on any organ,” which management say is a plus for very sick patients. Investing.com UK
The contest is playing out in hospital practices instead of a straightforward company-versus-company setup. Talphera wants to take share from, or cut down use of, heparin and citrate in CRRT circuits. CorMedix figures in as the closest public company angle after putting $5 million into Talphera last September. CorMedix CEO Joseph Todisco called Niyad a “potential significant improvement” over the current CRRT standard at the time. CorMedix
Analyst coverage on Wall Street is limited, so every new note tends to carry weight. Benzinga’s latest update shows WestPark Capital started coverage with a buy rating and a $3 price target on April 30. The consensus target from three analysts stands at $4.
But the downside is clear. Talphera’s latest quarterly filing showed zero revenue for the first quarter, R&D spend of $1.65 million, $2.30 million in selling, general and administrative costs, and a net loss of $2.56 million. The filing also warned about risks tied to needing more financing, staying on Nasdaq, burning cash, running trials, getting regulatory approval, and commercialization.
Trade is still narrow here and a bit shaky. Talphera shares are mostly tied to whatever comes first—last-patient-out or top-line data. It’s not really a broad biotech play. It’s a bet on one clinical timeline, whether the company has enough cash to get there, and if Niyad is finally what hospitals or regulators want for clotting in CRRT circuits.
